Navigation Links
Vaccine protects from deadly Hendra virus
Date:5/17/2011

CSIRO scientists have shown that a new experimental vaccine helps to protect horses against the deadly Hendra virus. Dr Deborah Middleton from CSIRO's Australian Animal Health Laboratory (AAHL) will announce the successful progress to develop the vaccine at the Australian Veterinary Association conference in Adelaide today.

"Our trials so far have shown that the vaccine prevents the infection of horses with Hendra virus," Dr Middleton said.

Stopping the disease in horses could also help protect people from the disease.

"A horse vaccine is crucial to breaking the cycle of Hendra virus transmission from flying foxes to horses and then to people, as it prevents both the horse developing the disease and passing it on," Dr Middleton said.

Hendra virus first appeared in 1994 and five of the 14 known outbreaks have spread to people. The virus has killed four of the seven people infected.

Depending on further development, field trials and registration the vaccine may be available as early as 2012.

Dr Barry Smyth, President of the Australian Veterinary Association, said that the news on the vaccine will be welcomed by both vets and horse owners.

"It's important that veterinarians and horse owners continue with precautions that reduce the risk of spreading the virus and that they report suspected cases immediately," Dr Smyth said. Recent work on evaluating the vaccine was jointly funded by the CSIRO, the Australian Government Department of Agriculture, Fisheries and Forestry and the Queensland Government Department of Employment, Economic Development and Innovation.

The development of the vaccine goes back more than ten years to shortly after CSIRO scientists first isolated the virus following the first outbreak of the disease in Hendra, Queensland.

Development and source of the vaccine is the result of a close collaboration with Dr Christopher Broder of the Uniformed Services University of the Health Sciences (the US federal health sciences university) supported by the US National Institutes of Health, but the high bio-containment facility at AAHL was essential for evaluating its beneficial effects.

"Our bio-security facility at AAHL is the only laboratory in the world where this work could have been done. It has been slow, painstaking and high-risk work and the credit is due to many people who've worked on this since 1994," Dr Middleton said.


'/>"/>

Contact: John Smith
John.M.Smith@csiro.au
61-732-142-960
CSIRO Australia
Source:Eurekalert

Related biology news :

1. Celiac disease vaccine shows promising results in Phase I trial
2. Study identifies promising target for AIDS vaccine
3. HIV protein unveils vaccine target
4. Allergy vaccine is nothing to sneeze at
5. Personlized dendritic cell vaccine increases survival in patients with deadly brain cancer
6. For first time, scientists show an HIV vaccine impacts the genetic makeup of the virus
7. Vaccine made with synthetic gene protects against deadly pneumonia
8. Media advisory -- Partnering to Fight TB: The Role of a TB Vaccine PDP
9. Saint Louis University findings: Dont pitch stockpiled avian flu vaccine
10. Researchers test inhalable measles vaccine
11. Therapeutic AIDS vaccine designed by HIVACAT reduces the viral load in the majority of AIDS patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology: